Hyderabad, May 21 : MSN Laboratories Private Limited (MSN) Today announced the launch of Posaconazole (PosaOne) in the Indian market to treat black fungus.
The product launched under the brand name ‘PosaOne’ as 100 mg Delayed Release tablets and 300 mg injections, respectively, Hyderabad-based Pharma company said in a release here.
Posaconazole is a triazole anti-fungal agent indicated for treating mucormycosis patients.
Many patients recovering from COVID-19 have been detected with a rare and deadly fungal infection known as mucormycosis or black fungus.
With mortality rates on the incline, accessibility of anti-fungal medication is being an unmet deficit in these testing times.
As an outcome of MSN’s competence in research and manufacturing of anti fungal infection drugs, it is now targeting to pro-actively reach patients across India by ensuring the access of PosaOne, through its strong distribution network and field force.
MSN has developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house R&D and manufacturing units.
The drug is approved by the Drugs Controller General of India (DGCI) and matches the International quality standards.
As part of the COVID treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg, OSELOW (Oseltamivir) as 75 mg capsules and also licensed Baridoz (Baricitinib) recently with Eli Lilly.
For availability of all COVID Drugs from MSN, patients can contact MSN COVID Helpline @ 91005 91030 or email to customercare@msnlabs.com for further assistance.
MSN has nine API and five finished dosage facilities in Hyderabad and the U.S.(UNI)